Neglected Burning Rock charms investors with high margins, narrowing losses
The cancer diagnostics company’s revenue rose slightly in the third quarter, as its gross margin rose by nearly 4 percentage points Key Takeaways: Burning Rock’s revenue rose 2.3% in the…
Armed with AstraZeneca deal, Eccogene files for Hong Kong IPO
The Chinese biotech is developing a weight-loss drug in a tablet form that could challenge leading products in the booming anti-obesity market Key Takeaways: The AstraZeneca licensing deal in 2023…
HBM notches up another mega deal but is the model sustainable?
The biotech has agreed to sell rights to one of its cancer drugs under development for up to $670 million, adding more fuel to its share price rebound this year…
A blockbuster cancer drug? TYK’s claims go under the microscope
The medicines company released scanty but promising results for an experimental drug just as its shares were joining the Hong Kong Stock Connect scheme Key Takeaways: The drug being developed…
Earnings blow for CSPC Pharma as the state drives a hard bargain
The generic drugs giant has warned of a 26% slide in annual profits after China’s national healthcare system imposed big price cuts on qualifying medicines Key Takeaways: CSPC Pharma…
AstraZeneca could face limited fallout from Chinese tax probe
The drugs giant and one of its top executives are being investigated over business tactics in China, but a potential fine for one alleged offence would not break the bank…
A McDonald’s Valuation Downsize, and New Medical Plan Additions
The value of McDonald's China operation has plunged by more than half in the last year. And 91 companies got their drugs added to China's national health plan By Doug…
Recent Articles
RELATED ARTICLES
-
Years of losses, thin profit margins leave 160 Health feeling down
2656.HK - With so many new IPOs, Quantgroup looks better left for high-risk investors
-
MoneyHero’s insurance and wealth shift boosts margins as it approaches profitability
MNY.US
-
Sany hopes Hong Kong investors see it as global high-tech heavy hitter
6031.HK600031.SHG
-
Precision cancer drugs show promise for Kelun-Biotech
6990.HK
-
Nio’s road to profitability obscured in haze of losses
9866.HKNIO.US
- ShanH seeks IPO recharge after years of losses
